SGI-7079

SGI-7079 is a selective, ATP-competitive, orally active inhibitor of the receptor tyrosine kinase Axl. SGI-7079 blocks Axl-mediated signaling pathways such as NF-κB activation and MMP-9 expression, thereby inhibiting tumor cell proliferation, migration and invasion. SGI-7079 is mainly used in the research of malignant tumors such as inflammatory breast cancer and bladder cancer, as well as in combination with immunization (used in combination with PD-1 therapy) [1][2][3].

Product Specifications

CAS Number

[1239875-86-5]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

TAM Receptor

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/SGI-7079.html

Purity

99.32

Solubility

DMSO : ≥ 34 mg/mL

Smiles

N#CCC1=CC=CC(C2=C3C(NC=C3C)=NC(NC4=CC=C(N5CCN(C)CC5)C(F)=C4)=N2)=C1

Molecular Formula

C26H26FN7

Molecular Weight

455.53

Precautions

H302, H315, H319, H335

References & Citations

[1]Wang X, et al. TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase. Cancer Res. 2013 Nov 1;73 (21) :6516-25.|[2]Wang SC, et al. Chidamide and mitomycin C exert synergistic cytotoxic effects against bladder cancer cells in vitro and suppress tumor growth in a rat bladder cancer model. Cancer Lett. 2022 Apr 1;530:8-15|[3]Guo Z, et al. Axl inhibition induces the antitumor immune response which can be further potentiated by PD-1 blockade in the mouse cancer models. Oncotarget. 2017 Sep 21;8 (52) :89761-89774.